A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

Blood

Volumn 120, Issue 14, 2012, Pages 2817-2825

  Siegel, David S ^a   Martin, Thomas ^b   Wang, Michael ^c   Vij, Ravi ^d   Jakubowiak, Andrzej J ^e   Lonial, Sagar ^f   Trudel, Suzanne ^g   Kukreti, Vishal ^g   Bahlis, Nizar ^h   Alsina, Melissa ⁱ   Chanan Khan, Asher ^j   Buadi, Francis ^k   Reu, Frederic J ^l   Somlo, George ^m   Zonder, Jeffrey ⁿ   Song, Kevin ^o   Stewart, A Keith ^p   Stadtmauer, Edward ^q   Kunkel, Lori ^r   Wear, Sandra ^s   Wong, Alvin F ^t   Orlowski, Robert Z ^c   Jagannath, Sundar ^u   more..

^a HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

^f EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF TORONTO   (Canada)

^h UNIVERSITY OF CALGARY   (Canada)

ⁱ H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^j MAYO CLINIC   (United States)

^k MAYO CLINIC   (United States)

^l TAUSSIG CANCER INSTITUTE   (United States)

^m CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

ⁿ WAYNE STATE UNIVERSITY   (United States)

^o UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^p MAYO CLINIC   (United States)

^q UNIVERSITY OF PENNSYLVANIA   (United States)

^r Mount Sinai Medical Center ^*

^s Multiple Myeloma Research Consortium   (United States)

^t ONYX PHARMACEUTICALS   (United States)

^u MOUNT SINAI MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CARFILZOMIB; DEXAMETHASONE; LENALIDOMIDE; THALIDOMIDE;

ACUTE KIDNEY FAILURE; ADULT; AGED; ANEMIA; ARTICLE; CANCER RECURRENCE; CONGESTIVE HEART FAILURE; CREATININE BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEART ARREST; HEART INFARCTION; HUMAN; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; NEUROPATHY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 84867295563     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-05-425934     Document Type: Article

References (55)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10-29.
2. Mohty B, El-Cheikh J, Yakoub-Agha I, Avet-Loiseau H, Moreau P, Mohty M. Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and 'retreatment' approaches in the era of novel agents. Leukemia. 2012;26(1):73-85.
3. Edwards BK, Ward E, Kohler BA, et al. Annual report to the nation on the status of cancer, 1975- 2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010; 116(3):544-573.
4. Offidani M, Leoni P, Corvatta L, et al. Outcome and toxicity in the modern era of new drugs for multiple myeloma: a reappraisal for comparison with future investigational trials. Clin Lymphoma Myeloma Leuk. 2010;10(5):353-360.
5. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277-300.
6. van de Donk NW, Lokhorst HM, Dimopoulos M, et al. Treatment of relapsed and refractory multiple myeloma in the era of novel agents. Cancer Treat Rev. 2011;37(4):266-283.
7. Richardson PG, Laubach J, Mitsiades C, et al. Tailoring treatment for multiple myeloma patients with relapsed and refractory disease. Oncology (Williston Park). 2010;24(3 Suppl 2):22-29.
8. Mitsiades CS, Davies FE, Laubach JP, et al. Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma. J Clin Oncol. 2011;29(14):1916-1923.
9. Jung T, Catalgol B, Grune T. The proteasomal system. Mol Aspects Med. 2009;30(4):191-296.
10. Rolfe M, Chiu MI, Pagano M. The ubiquitin-mediated proteolytic pathway as a therapeutic area. J Mol Med. 1997;75(1):5-17. (Pubitemid 27067134)
11. Ciechanover A. Proteolysis: from the lysosome to ubiquitin and the proteasome. Nat Rev Mol Cell Biol. 2005;6(1):79-87.
12. Wan F, Lenardo MJ. The nuclear signaling of NFkappaB: current knowledge, new insights, and future perspectives. Cell Res. 2010;20(1):24-33.
13. Zhang HG, Wang J, Yang X, Hsu HC, Mountz JD. Regulation of apoptosis proteins in cancer cells by ubiquitin. Oncogene. 2004;23(11):2009-2015. (Pubitemid 38496730)
14. Kane RC, Bross PF, Farrell AT, Pazdur R. Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist. 2003;8(6):508-513. (Pubitemid 37467365)
15. Kane RC, Farrell AT, Sridhara R, Pazdur R. United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy. Clin Cancer Res. 2006;12(10):2955- 2960. (Pubitemid 43837337)
16. Kane RC, Dagher R, Farrell A, et al. Bortezomib for the treatment of mantle cell lymphoma. Clin Cancer Res. 2007;13(18):5291-5294. (Pubitemid 47510352)
17. Demo SD, Kirk CJ, Aujay MA, et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res. 2007;67(13):6383-6391. (Pubitemid 47037522)
18. Kuhn DJ, Chen Q, Voorhees PM, et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood. 2007;110(9):3281-3290. (Pubitemid 350106321)
19. Parlati F, Lee S, Aujay M, et al. Carfilzomib: a selective inhibitor of the chymotrypsin-like activity of the constitutive proteasome and immunoproteasome has anti-tumor activity on multiple myeloma, lymphoma, and leukemia cells with minimal effects on normal cells. Haematologica. 2009;94(Suppl 2):0373.
20. Arastu-Kapur S, Anderl JL, Kraus M, et al. Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. Clin Cancer Res. 2011;17(9):2734-2743.
21. Kirk CJ, Jiang J, Muchamuel T, et al. The selective proteasome inhibitor carfilzomib is well tolerated in experimental animals with dose intensive administration [abstract]. Blood (ASH Annual Meeting Abstracts). 2008;112(11). Abstract 2765.
22. Bruna J, Udina E, Ale A, et al. Neurophysiological, histological and immunohistochemical characterization of bortezomib-induced neuropathy in mice. Exp Neurol. 2010;223(2):599-608.
23. Poruchynsky MS, Sackett DL, Robey RW, Ward Y, Annunziata C, Fojo T. Proteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells: a possible mechanism contributing to peripheral neuropathy and cellular toxicity following proteasome inhibition. Cell Cycle. 2008;7(7):940-949. (Pubitemid 351573790)
24. O'Connor OA, Stewart AK, Vallone M, et al. A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. Clin Cancer Res. 2009; 15(22):7085-7091.
25. Alsina M, Trudel S, Furman RR, et al. A phase 1 single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma. Clin Cancer Res. 2012;18(17):4830-4840.
26. Jagannath S, Vij R, Stewart K, et al. Final results of PX-171-003-A0, part 1 of an open label, single-arm, phase II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM) [abstract]. J Clin Oncol. 2009;27(15 Suppl). Abstract 8504.
27. Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT: European Group for Blood and Marrow Transplant. Br J Haematol. 1998;102(5):1115-1123. (Pubitemid 28435189)
28. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467-1473. (Pubitemid 44264086)
29. Simon R, Makuch RW. A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias. Stat Med. 1984;3(1):35-44. (Pubitemid 14142275)
30. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348(26):2609- 2617. (Pubitemid 36741588)
31. Calhoun EA, Welshman EE, Chang CH, et al. Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer. 2003;13(6): 741-748. (Pubitemid 38235217)
32. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Amer Statist Assn. 1958;53:457-481.
33. Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996;17(4):343-346. (Pubitemid 26342716)
34. Singhal S, Siegel DS, Martin T, et al. Integrated safety from phase 2 studies of monotherapy carfilzomib in patients with relapsed and refractory multiple myeloma (MM): an updated analysis [abstract]. Blood (ASH Annual Meeting Abstracts). 2011;118(21). Abstract 1876.
35. Siegel D, Kaufman J, Wang M, et al. A summary of safety and efficacy data achieved with long-term carfilzomib (CFZ) treatment in patients with relapsed and/or refractory multiple myeloma (R/R MM) [abstract]. Haematologica. 2011;96(Suppl 2):126. Abstract 0302
36. Kumar SK, Lee JH, Lahuerta JJ, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter International Myeloma Working Group study. Leukemia. 2012;26(1):149-157.
37. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352(24):2487- 2498. (Pubitemid 41007864)
38. Anderson KC, Kyle RA, Rajkumar SV, Stewart AK, Weber D, Richardson P. Clinically relevant end points and new drug approvals for myeloma. Leukemia. 2008;22(2):231-239. (Pubitemid 351250526)
39. Jakubowiak AJ, Dytfeld D, Griffith KA, et al. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood. 2012;120(9):1801-1809.
40. Mikhael JR. A phase I/II trial of cyclophosphamide, carfilzomib, thalidomide, and dexamethasone (CYCLONE) in patients with newly diagnosed multiple myeloma [abstract]. J Clin Oncol. 2012;30(15). Abstract 8010.
41. Sonneveld P, Hacker E, Zweegman S, et al. Carfilzomib combined with thalidomide and dexamethasone (CARTHADEX) as induction treatment prior to high-dose melphalan (HDM) in newly diagnosed patients with multiple myeloma (MM): a trial of the European Myeloma Network EMN [abstract]. Blood (ASH Annual Meeting Abstracts). 2011;118(21). Abstract 633.
42. Squifflet P, Michiels S, Siegel DS, Vij R, Ro SK, Buyse M. Multivariate modelling reveals evidence of a dose-response relationship in phase 2 studies of single-agent carfilzomib [abstract]. Blood (ASH Annual Meeting Abstracts). 2011;118(21). Abstract 1877.
43. Papadopoulos KP, Lee P, Singhal S, et al. A phase 1b/2 study of prolonged infusion carfilzomib in patients with relapsed and/or refractory (R/R) multiple myeloma: updated efficacy and tolerability from the completed 20/56 mg/m2 expansion cohort of PX-171-007 [abstract]. Blood (ASH Annual Meeting Abstracts. 2011;118(21). Abstract 2930.
44. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009;23(1): 3-9.
45. Gay F, Palumbo A. Management of disease- and treatment-related complications in patients with multiple myeloma. Med Oncol. 2010;27(Suppl 1):S43-S52.
46. Lonial S, Waller EK, Richardson PG, et al. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood. 2005;106(12):3777-3784. (Pubitemid 41739012)
47. Mohty B, El-Cheikh J, Yakoub-Agha I, Moreau P, Harousseau JL, Mohty M. Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations. Haematologica. 2010;95(2):311-319.
48. Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011;12(5):431-440.
49. Arnulf B, Pylypenko H, Grosicki S, et al. Updated survival analysis of a randomized, phase 3 study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma [published online ahead of print June 11, 2012]. Haematologica. doi: 10.3324/haematol. 2012.067793.
50. Richardson PG, Sonneveld P, Schuster MW, et al. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol. 2009;144(6):895-903.
51. Harvey D, Lonial S, Patel P, McCulloch L, Niesvizky R, Kaufman J. Carfilzomib dose and schedule need not be adjusted for baseline renal dysfunction, including patients on hemodialysis [abstract]. Haematologica. 2012;97(Suppl 2). Abstract 0844.
52. Millennium Pharmaceuticals. Velcade Prescribing Information. Cambridge, MA: Millennium Pharmaceuticals; 2012.
53. Richards T, Weber D. Advances in treatment for relapses and refractory multiple myeloma. Med Oncol. 2010;27(Suppl 1):S25-S42.
54. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Multiple Myeloma. Version 1.2012. Fort Washington, PA: National Comprehensive Cancer Network; 2012.
55. Niesvizky R, Bensinger W, Martin T, et al. An update on the phase 1b/2 dose-escalation study of carfilzomib with lenalidomide and low-dose dexamethasone (CRd) in patients with relapsed or refractory multiple myeloma [abstract 0295]. Haematologica. 2011;96(Suppl 2):122.